Compile Data Set for Download or QSAR
Report error Found 124 Enz. Inhib. hit(s) with all data for entry = 7646
TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM50105085(US9233167, Nalbuphine | 17-cyclobutylmethyl-4,5alp...)
Affinity DataEC50:  25.1nMpH: 7.4 T: 2°CAssay Description:Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208977(US9233167, 6-O-mPEG3-Nalbuphine)
Affinity DataEC50:  26.8nMpH: 7.4 T: 2°CAssay Description:Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208978(US9233167, 6-O-mPEG6-Nalbuphine)
Affinity DataEC50:  164nMpH: 7.4 T: 2°CAssay Description:Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208979(US9233167, 6-O-mPEG9-Nalbuphine)
Affinity DataEC50:  485nMpH: 7.4 T: 2°CAssay Description:Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208981(US9233167, Morphine | (4R,4aR,7S,7aR,12bS)-3-methy...)
Affinity DataEC50:  28.5nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208982(US9233167, a-6-mPEG1-O-Morphine)
Affinity DataEC50:  85nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208983(US9233167, a-6-mPEG2-O-Morphine)
Affinity DataEC50:  93.3nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208984(US9233167, a-6-mPEG3-O-Morphine)
Affinity DataEC50:  270nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208985(US9233167, a-6-mPEG4-O-Morphine)
Affinity DataEC50:  128nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208986(US9233167, a-6-mPEG5-O-Morphine)
Affinity DataEC50:  157nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208987(US9233167, a-6-mPEG6-O-Morphine)
Affinity DataEC50:  415nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208988(US9233167, a-6-mPEG7-O-Morphine)
Affinity DataEC50:  508nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208989(US9233167, a-6-mPEG9-O-Morphine)
Affinity DataEC50:  1.06E+3nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM50370595(US9233167, Oxycodone | Oxycontin | OXYCODONE | US1...)
Affinity DataEC50:  478nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208990(US9233167, a-6-mPEG1-O-Hydroxycodone)
Affinity DataEC50:  3.84E+3nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208991(US9233167, a-6-mPEG2-O-Hydroxycodone)
Affinity DataEC50:  5.01E+3nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208992(US9233167, a-6-mPEG3-O-Hydroxycodone)
Affinity DataEC50:  2.83E+3nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208993(US9233167, a-6-mPEG4-O-Hydroxycodone)
Affinity DataEC50:  3.72E+3nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208994(US9233167, a-6-mPEG5-O-Hydroxycodone)
Affinity DataEC50:  5.04E+3nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208995(US9233167, a-6-mPEG5-O-Hydroxycodone)
Affinity DataEC50:  1.25E+4nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208996(US9233167, a-6-mPEG5-O-Hydroxycodone)
Affinity DataEC50:  7.45E+3nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208997(US9233167, a-6-mPEG5-O-Hydroxycodone)
Affinity DataEC50:  1.79E+4nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208998(US9233167, Codeine | (4R,4aR,7S,7aR,12bS)-9-methox...)
Affinity DataEC50:  1.04E+4nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208980(US9233167, a-6-mPEG1-O-Codeine)
Affinity DataEC50:  8.57E+3nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208999(US9233167, a-6-mPEG2-O-Codeine)
Affinity DataEC50:  5.15E+3nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM209000(US9233167, a-6-mPEG3-O-Codeine)
Affinity DataEC50:  1.97E+4nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM209001(US9233167, a-6-mPEG3-O-Codeine)
Affinity DataEC50:  2.21E+4nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM209002(US9233167, a-6-mPEG3-O-Codeine)
Affinity DataEC50:  2.32E+4nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM209003(US9233167, a-6-mPEG3-O-Codeine)
Affinity DataEC50:  9.74E+4nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM209004(US9233167, a-6-mPEG3-O-Codeine)
Affinity DataEC50:  4.47E+4nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM209005(US9233167, a-6-mPEG3-O-Codeine)
Affinity DataEC50:  4.82E+4nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM209006(US9233167, Hydroxycodone)
Affinity DataEC50:  3.16E+3nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208981(US9233167, Morphine | (4R,4aR,7S,7aR,12bS)-3-methy...)
Affinity DataEC50:  624nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208982(US9233167, a-6-mPEG1-O-Morphine)
Affinity DataEC50:  1.19E+3nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208983(US9233167, a-6-mPEG2-O-Morphine)
Affinity DataEC50:  641nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208984(US9233167, a-6-mPEG3-O-Morphine)
Affinity DataEC50:  4.20E+3nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208985(US9233167, a-6-mPEG4-O-Morphine)
Affinity DataEC50:  3.09E+3nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208986(US9233167, a-6-mPEG5-O-Morphine)
Affinity DataEC50:  2.30E+3nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208987(US9233167, a-6-mPEG6-O-Morphine)
Affinity DataEC50:  3.93E+3nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208988(US9233167, a-6-mPEG7-O-Morphine)
Affinity DataEC50:  4.24E+3nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208989(US9233167, a-6-mPEG9-O-Morphine)
Affinity DataEC50:  4.42E+3nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208999(US9233167, a-6-mPEG2-O-Codeine)
Affinity DataEC50:  4.01E+4nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208978(US9233167, 6-O-mPEG6-Nalbuphine)
Affinity DataIC50: 284nMpH: 7.4 T: 2°CAssay Description:Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208977(US9233167, 6-O-mPEG3-Nalbuphine)
Affinity DataIC50: 398nMpH: 7.4 T: 2°CAssay Description:Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM50105085(US9233167, Nalbuphine | 17-cyclobutylmethyl-4,5alp...)
Affinity DataIC50: 752nMpH: 7.4 T: 2°CAssay Description:Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208979(US9233167, 6-O-mPEG9-Nalbuphine)
Affinity DataIC50: 1.01E+3nMpH: 7.4 T: 2°CAssay Description:Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetDelta-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208979(US9233167, 6-O-mPEG9-Nalbuphine)
Affinity DataIC50: 8.97E+3nMpH: 7.4 T: 2°CAssay Description:Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208981(US9233167, Morphine | (4R,4aR,7S,7aR,12bS)-3-methy...)
Affinity DataKi:  8.44nM ΔG°:  -46.1kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM50105085(US9233167, Nalbuphine | 17-cyclobutylmethyl-4,5alp...)
Affinity DataKi:  14.3nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208982(US9233167, a-6-mPEG1-O-Morphine)
Affinity DataKi:  15.7nM ΔG°:  -44.5kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 124 total ) | Next | Last >>
Jump to: